These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36104978)

  • 21. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
    Zhu J; Li Y; Lv X
    Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UBE2V2 Positively Correlates With PD-L1 Expression and Confers Poor Patient Survival in Lung Adenocarcinoma.
    Hua ZD; Liu XB; Sheng JH; Li C; Li P; Cai XQ; Han ZQ
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):585-591. PubMed ID: 33734107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
    Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
    Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
    Jin G; Ma M; Yang C; Zhen L; Feng M
    Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
    Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
    Front Immunol; 2022; 13():983570. PubMed ID: 36275753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.
    Cui Y; Li J; Zhang P; Yin D; Wang Z; Dai J; Wang W; Zhang E; Guo R
    J Exp Clin Cancer Res; 2023 Jun; 42(1):146. PubMed ID: 37303063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.
    Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
    Clin Epigenetics; 2021 Dec; 13(1):229. PubMed ID: 34933667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
    J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
    Liu C; Li Z; Wang S; Fan Y; Zhang S; Yang X; Hou K; Tong J; Hu X; Shi X; Wang X; Liu Y; Che X; Qu X
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):65-76. PubMed ID: 30357521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
    Zhao F; Wang M; Zhu J
    Cancer Med; 2021 Sep; 10(17):6099-6113. PubMed ID: 34250747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 40. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
    Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
    Front Oncol; 2022; 12():904969. PubMed ID: 35978822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.